Inhibiting CD49B/CD29 for thrombosis

Inhibiting the integrin α2β1, also known as CD49B/CD29, could help treat thrombosis by decreasing its interaction with the acylcarnitine metabolite 2MBC in platelets, which prevents activation of the phospholipase CPLA2, and thus inhibits platelet hyperresponsiveness.

Metabolomic analysis identified higher 2MBC levels in fecal samples from COVID-19 patients, who have elevated risk for thrombotic events, than in samples from healthy individuals or non-COVID-19 hospitalized patients, and higher 2MBC levels were associated with clinical parameters linked to thrombotic cardiovascular diseases, such as D-dimer levels. ...